Drugs / hu14.18-IL2
hu14.18-IL2
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03209869 | Mar 2018 → Sep 2022 | neuroblastoma, osteosarcoma | University of Wisconsin, Madison | Withdrawn | No outcome recorded |
| Phase 1 | NCT00003750 | Oct 2001 → Jan 2005 | childhood malignant neoplasm, cutaneous melanoma, neuroblastoma, sarcoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03958383 | Jan 2020 → Jan 2024 | melanoma | University of Wisconsin, Madison | Terminated | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT01334515 | Sep 2011 → Dec 2013 | neuroblastoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00590824 | Dec 2007 → Sep 2018 | melanoma | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 2 | NCT00109863 | May 2005 → Jul 2007 | cutaneous melanoma | University of Wisconsin, Madison | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hu14.18-IL2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00590824 ↗ |
| Known as | EMD273063 | “A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group.” PMID 16551859 ↗ Mar 20062“A Pilot Trial of HU14.18-IL2 (EMD273063) in Subjects With Completely Resectable Recurrent Stage III or Stage IV Melanoma” NCT00590824 ↗ “Hu14.18-IL2 (EMD 273063) in Subjects With Advanced Melanoma” NCT00109863 ↗ |
| Known as | hu14.18-IL2 fusion protein | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01334515 ↗ |
| Known as | hu14.18-interleukin-2 | “Patients receive hu14.18-interleukin-2 (hu14.18-IL2) fusion protein IV over 4 hours once daily on days 1-3.” NCT00003750 ↗ |
| Action | Deplete | “The antibody portion (hu14.18) of the immunocytokine molecule "flags" the neuroblastoma cells for destruction by NK cells” NCT03209869 ↗ |
| Modality | Monoclonal antibody | “a humanized anti-GD2 monoclonal antibody linked to human interleukin 2 (IL-2)” PMID 16551859 ↗ Mar 2006 |
| Route | Intravenous | “given intravenously over 4 hours” NCT00003750 ↗ |